Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
Recruiting · NCT05933733 · Observational (researchers observe without assigning treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer. The main questions it aims to answer are: * Clinical outcomes after salvage treatment for locoregional recurrence * Adverse events and quality of life after salvage treatment for locoregional recurrence * Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events * Molecular signature associated with treatment resistance Participants will be assessed by multi-dimensional methods during and after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0 * Assessment for the molecular signature using residual tissue after pathologic diagnosis * Assessment for the quality of life using questionnaires (BREAST-Q)
Who can take part
Inclusion criteria
- Female patients with age 18 to 100.
- Previous standard definitive treatment for initial breast cancer
- Locoregional recurrence without distant metastasis
- Planned salvage treatment for locoregional recurrence
- Informed consent of the participant
Exclusion criteria
- \- Not anticipated for complying the study protocol
Where it is running
1 location listed.
- Samsung Medical Center - Seoul, South Korea